Literature DB >> 10232497

Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial.

L Vaur1, B Vaisse, N Genes, F Elkik, C Legrand, L Poggi.   

Abstract

The objective of the present study was to determine the predictive factors of treatment compliance in hypertensive patients. This was an open large-scale multicenter study where mild to moderate essential hypertensive patients received trandolapril (2 mg) once daily for 30 to 60 days in addition to their usual treatment. Trandolapril was packed in electronic pill boxes that registered date and time of each opening. The main compliance parameters were the percentage of missed doses, the percentage of delayed doses, and the percentage of correct dosing periods. Predictive factors of poor compliance (correct dosing periods < 80%) were determined using a multivariate stepwise logistic regression analysis. Two thousand one hundred seventy-three patients aged 60 +/- 12 years were analyzed. Of the total patients 37% were poor compliers; 29% of patients forgot more than 10% of doses and 36% of patients delayed more than 10% of doses. Ranked predictive factors of poor compliance were: age < 60 years (odds ratio [OR], 1.80 [1.49 to 2.17], P = .0001), the Paris area (OR, 1.70 [1.32 to 2.19], P = .0001), smokers (OR, 1.65 [1.29 to 2.11], P = .0001), monotherapy (OR, 1.40 [1.14 to 1.72], P = .0012), and baseline diastolic blood pressure > or = 100 mm Hg (OR, 1.21 [1.01 to 1.46], P = .044). Therefore, we conclude that young hypertensives, large city dwellers, and smokers are more likely to be poor compliers. The presence of some of these characteristics might incite the physician either to encourage patient compliance or to prescribe antihypertensive drugs that have an effect that persists even beyond 24 h.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232497     DOI: 10.1016/s0895-7061(98)00274-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

1.  The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response.

Authors:  John Urquhart
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 2.  Hypertension and current issues in compliance and patient outcomes.

Authors:  T M Zyczynski; K S Coyne
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

3.  Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care.

Authors:  Andreas Zeller; Knut Schroeder; Tim J Peters
Journal:  Scand J Prim Health Care       Date:  2007-12       Impact factor: 2.581

4.  Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

Authors:  F D A Reid; D G Cook; P H Whincup
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

Review 5.  Why are we doing so badly with the control of hypertension? Poor compliance is only part of the story.

Authors:  T G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

6.  A cohort study of possible risk factors for over-reporting of antihypertensive adherence.

Authors:  P W Choo; C S Rand; T S Inui; M L Lee; C Canning; R Platt
Journal:  BMC Cardiovasc Disord       Date:  2001-12-13       Impact factor: 2.298

7.  [Drug compliance and its factors in a group of hypertensive Congolese].

Authors:  Méo Stéphane Ikama; Bernice Mesmer Nsitou; Mpouoni Loumouamou; Gisèle Kimbally-Kaky; Jean Louis Nkoua
Journal:  Pan Afr Med J       Date:  2013-08-06

Review 8.  Compliance with the treatment of hypertension: the potential of combination therapy.

Authors:  Serap Erdine
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

9.  Initial antihypertensive prescription and switching: a 5 year cohort study from 250,851 patients.

Authors:  Martin C S Wong; Wilson W S Tam; Clement S K Cheung; Ellen L H Tong; Antonio C H Sek; George John; N T Cheung; Bryan P Y Yan; C M Yu; Stephen Leeder; Sian Griffiths
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).

Authors:  Cornel Pater
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.